GOLDSMITH MARK A sold $1.3M of RVMD (indirect holdings)
GOLDSMITH MARK A (See Remarks) sold 6,000 indirectly-held shares of Revolution Medicines, Inc. (RVMD) at an average of $209.20 ($207.25–$212.06, $1.26M total) across 12 trades on 2026-08-21 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh data on insider sentiment, which traders may incorporate into short‑term positioning.
Market read
Insider sale of $1.3 M in RVMD may influence short‑term price action and sentiment in the biotech sector.
What to watch
Upcoming clinical trial data could offset any negative perception from the sale.
Background
SEC Form 4 filing discloses insider transactions; such filings are primary sources of corporate insider activity.
Ticker impact
Officer Mark Goldsmith sold 6,000 RVMD shares for $1.3M under a 10b5‑1 plan on 2026‑08‑21.
Potential modest downside of 2‑4% over the next few days.
The sale size (~$1.3M) is material for a mid‑cap biotech and was executed via a pre‑arranged plan, suggesting a neutral to slightly bearish impact.
Market effects
May raise concerns among biotech investors about insider sentiment.
Limited to US biotech sector; no broader regional effect.
Minimal global impact; primarily relevant to RVMD shareholders.
Counterpoint
The 10b5‑1 plan could be routine liquidity management, not a bearish signal.
Key entities
- CompanyRevolution Medicines, Inc.
Biotech firm listed on NASDAQ under ticker RVMD.
- OfficerMark Goldsmith
Director/officer of Revolution Medicines who sold shares.
